In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
- PMID: 37399559
- DOI: 10.7326/J23-0048
In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
Erratum in
-
Corrections to ACP Journal Club: Errors in Clinical Impact Ratings.Ann Intern Med. 2023 Dec;176(12):JC144. doi: 10.7326/J23-0087. Epub 2023 Oct 3. Ann Intern Med. 2023. PMID: 37782926 No abstract available.
Abstract
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-1171. 36871574.
Conflict of interest statement
Comment on
-
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2. Lancet. 2023. PMID: 36871574 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical